Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines Corrigendum in /10.3892/ijo.2016.3613

Ibrahim,Toni; Liverani,Chiara; Mercatali,Laura; Sacanna,Emanuele; Zanoni,Michele; Fabbri,Francesco; Zoli,Wainer; Amadori,Dino

doi:10.3892/ijo.2013.1809

Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines

Corrigendum in: /10.3892/ijo.2016.3613

Authors:
- Toni Ibrahim
- Chiara Liverani
- Laura Mercatali
- Emanuele Sacanna
- Michele Zanoni
- Francesco Fabbri
- Wainer Zoli
- Dino Amadori
View Affiliations

Affiliations: Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), I-47014 Meldola (FC), Italy, Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), I-47014 Meldola (FC), Italy
Published online on: February 6, 2013 https://doi.org/10.3892/ijo.2013.1809
Pages: 1263-1270

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zoledronic acid (ZA) is the most widely used bisphosphonate to treat cancer-induced bone disease. There is evidence that bisphosphonates have direct antitumor activity and that their combination with anticancer agents can significantly enhance the effect of treatment. We evaluated whether the combination of ZA with different platinum compounds exerts a synergistic effect in breast cancer cell lines and we investigated the mechanisms of action involved. This study was performed on four breast cancer cell lines, MCF-7, SKBR3, MDA-MB-231 and BRC-230, and confirmed on a primary culture obtained from a breast cancer bone metastasis specimen. ZA (50 µM) was administered for 72 h alone or in combination with cisplatin (Cis) or carboplatin. Drug-induced growth inhibition was detected by sulforhodamine B assay, apoptosis and cell cycle regulation were detected by flow cytometry, and protein expression was evaluated by western blot analysis. MCF-7 and SKBR3 showed very low sensitivity to the three drugs tested. The ZA + Cis combination exerted a high antitumor activity in the two triple-negative lines MDA-MB-231 and BRC-230. An important synergistic effect was obtained in MDA-MB-231 and an additive effect was observed in BRC-230. The p21, pMAPK and m-TOR pathways were regulated by this combined treatment, particularly at lower Cis doses. Carboplatin did not show antitumor activity either alone or in combination with ZA. In conclusion, the potential novel treatment schedule identified for triple-negative breast cancer could prove beneficial in view of the limited therapeutic options available for patients and also since the synergism with ZA would enable lower Cis doses to be used, thus reducing toxicity. Although further research in a clinical setting is warranted, our results on cell lines has been confirmed on a human primary bone metastasis culture.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer. 55:61–66. 1987. View Article : Google Scholar : PubMed/NCBI
3	Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG and Pritchard KL: Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol. 26:5465–5476. 2008. View Article : Google Scholar : PubMed/NCBI
4	Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer. 98:1736–1740. 2008. View Article : Google Scholar : PubMed/NCBI
5	Coleman RE and McCloskey EV: Bisphosphonates in oncology. Bone. 49:71–76. 2011. View Article : Google Scholar
6	Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE and Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase in cholesterol biosynthesis. J Lipid Res. 33:1657–1663. 1992.PubMed/NCBI
7	Van Beek E, Pieterman E, Cohen L, Lowick C and Papapoulos S: Farnesyl pyrophosphatase synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264:108–111. 1999.
8	Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A and Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 15:1467–1476. 2000. View Article : Google Scholar : PubMed/NCBI
9	Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2961–2978. 2000. View Article : Google Scholar : PubMed/NCBI
10	Benford HL, McGowan NW, Helfrich MH, Nuttall ME and Rogers MJ: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 28:465–473. 2001. View Article : Google Scholar : PubMed/NCBI
11	Jagdev SP, Coleman RE, Shipman CM, Rostami HA and Croucher PI: The bisphosphonate, ZA, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 84:1126–1134. 2001. View Article : Google Scholar : PubMed/NCBI
12	Senaratne SG, Pirianov G, Mansi JL, Arnett T and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 82:1459–1468. 2000. View Article : Google Scholar : PubMed/NCBI
13	Derenne S, Amiot M, Barille S, et al: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 14:2048–2056. 1999. View Article : Google Scholar : PubMed/NCBI
14	Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61:2602–2608. 2001.PubMed/NCBI
15	Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 98:665–672. 1997. View Article : Google Scholar : PubMed/NCBI
16	Van der Pluijm G, Vloedgraven H, van Beek EJ, van der Wee-Pals L, Lowik C and Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 98:698–705. 1996.
17	Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57:3890–3894. 1997.PubMed/NCBI
18	Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60:2949–2954. 2000.PubMed/NCBI
19	Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L and Foidart JM: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
20	Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE and Holen I: Sequence- and schedule-dependent enhancement of ZA induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 113:364–371. 2005. View Article : Google Scholar : PubMed/NCBI
21	Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate ZA and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 27:92–103. 2006. View Article : Google Scholar : PubMed/NCBI
22	Vogt U, Bielawski KP, Bosse U and Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 12:1109–1114. 2004.
23	Zhao X, Xu X, Guo L, et al: Biomarker alterations with metronomic use of low-dose ZA for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat. 124:733–743. 2010. View Article : Google Scholar : PubMed/NCBI
24	Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M and Bignon YJ: Molecular insights on basal-like breast cancer. Breast Cancer Res Treat. 134:21–30. 2012. View Article : Google Scholar : PubMed/NCBI
25	Sirohi B, Arnedos M, Popat S, et al: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 19:1847–1852. 2008. View Article : Google Scholar : PubMed/NCBI
26	Amadori D, Bertoni L, Flamigni A, et al: Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat. 28:251–260. 1993. View Article : Google Scholar : PubMed/NCBI
27	Skehan P, Storeng R, Scudiero D, et al: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
28	Monks A, Scudiero D, Skehan P, et al: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 83:757–766. 1991. View Article : Google Scholar : PubMed/NCBI
29	Kern DH, Morgan CR and Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res. 48:117–121. 1988.PubMed/NCBI
30	Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M and Zunino F: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol. 41:385–390. 1998. View Article : Google Scholar : PubMed/NCBI
31	Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H and Bache M: Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol. 5:822010. View Article : Google Scholar : PubMed/NCBI
32	Senaratne SG, Mansi JL and Colston KW: The bisphosphonate ZA impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer. 86:1479–1486. 2002.
33	Rachner TD, Singh SK, Schoppet M, et al: ZA induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett. 287:109–116. 2010. View Article : Google Scholar : PubMed/NCBI
34	Guise TA: Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 34:19–24. 2008. View Article : Google Scholar : PubMed/NCBI
35	Fabbri F, Brigliadori G, Carloni S, et al: Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 6:432008. View Article : Google Scholar : PubMed/NCBI
36	Curigliano G and Goldhirsch A: Triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr. 108–110. 2011. View Article : Google Scholar : PubMed/NCBI
37	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
38	Benassi MS, Chiechi A, Ponticelli F, et al: Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 250:194–205. 2007. View Article : Google Scholar : PubMed/NCBI
39	Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S and Yildiz M: Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int. 31:1069–1071. 2007. View Article : Google Scholar : PubMed/NCBI
40	Fujise K, Zhang D, Liu J and Yeh ET: Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem. 275:39458–39465. 2000. View Article : Google Scholar : PubMed/NCBI
41	Ellard SL, Clemons M, Gelmon KA, et al: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCI Clinical Trials Group IND.163. J Clin Oncol. 27:4536–4541. 2009. View Article : Google Scholar : PubMed/NCBI
42	Steelman LS, Navolanic P, Chappell WH, et al: Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 10:3003–3015. 2011. View Article : Google Scholar : PubMed/NCBI
43	Gaur S, Chen L, Yang L, Wu X, Un F and Yen Y: Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Cancer Lett. 311:20–28. 2011. View Article : Google Scholar : PubMed/NCBI
44	Moriceau G, Ory B, Mitrofan L, et al: Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 70:10329–10339. 2010. View Article : Google Scholar : PubMed/NCBI
45	Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P and Holen I: Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 14:4658–4666. 2008. View Article : Google Scholar : PubMed/NCBI
46	Coleman RE, Winter MC, Cameron D, et al: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 102:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI